CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 – 9MG

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend

The three synthesized peptides (CJC-1295 Mod GRF 1-29, Ipamorelin, and GHRP-2), as recommended by scientific research groups may be able to boost the secretion of growth hormone. These enzymes are used at times in us as well for the most part under the brand name Humapen The 3 different peptides appear to be functioning quite possibly together, therefore supplying some unique peptide activity.

CJC-1295/Mod GRF 1-29 respectively act as an agonist to the receptor of endogenously expressed growth hormone-releasing hormone (GHRH). It is an analogue of its truncated version called GHRH (1-29) which seems to have the same potential affinity for receptors. GHRH 1-29 is likely shortest bioactive core of GHRH comprising the first 29 amino acids. CJC-1295 (Mod GRF 1-29) is a variation of the peptide that has been tetrasubstituted and further modified with the addition of a drug affinity complex (DAC) element called N-epsilon-3-maleimidopropionamide. This higher component has the ability to bind maybe with plasma proteins which may increase its pharmacokinetic activity of CJC-1295 (Mod GRF 1-29).

Ipamorelin: A pentapeptide that mimics the common natural hunger hormone ghrelin Another hormone (growth-hormone-releasing hormone) is also involved in gastric emptying and may act to signal the ghrelin receptors as well, which could cause the release of GH mediated by the Growth Hormone Secretagogue receptor.

Growth Hormone Releasing Peptide 2-Short GHRP-2 (Hexapeptide) It is a synthetic analogue of the GHS-R1a peptide hormone ghrelin. It seems that GHRP-2 and Ipamorelin peptides activate GHS-R1a and thereby hypothetically cause a release of growth hormone. Yet a reported function at ghrelin receptors would also suggest potential effects. Researchers call them Growth Hormone Secretagogues (GHSs) for this reason.

Many human experiments have shown that it can increase growth hormone levels in people with deficiency. This study along with the previously discussed ones — are for educational and research purposes only; such studies do not reach a conclusion on how the peptide works. In those clinical trials, the peptide mimicked GH-releasing action in two ways -- either by acting on the pituitary gland to release GH or directly working at the arcuate nucleus of hypothalamus. Even though these peptides (including GHRP-2, Ipamorelin, CJC-1295(Mod GRF 1-29) displayed in vitro properties of high GH release, it is not currently clear which of the two mechanisms either or both worked. Furthermore, it had been postulated that these peptides could alter food intake, cardiac tone and sleep all through the action of an apparently selective receptor and so far follow-up studies had actually confirmed these postulations.

In another study, six test subjects suffering from severe growth retardation and a deficiency of endogenous growth hormone resulting in failure to grow were given growth hormone-releasing peptides. Episodic growth hormone secretion and toxicity levels were monitored in all subjects over this 30-h period. The experimental findings with this in-depth study of it were that there was what the researchers reported as only minimal elevation (as can be seen in the graph) was detected, and which increased gradually during their experiment declined slowly afterwards. According to V. Mericq et al, the trials show that the peptides were "well tolerated and […] promote GH secretion. Research is ongoing, including studies such as this, and plenty more work on the peptides.

THE CONTENT ON THIS WEBSITE IS STRICTLY INFORMATIONAL. IT IS NOT INTENDED TO BE TAKEN AS MEDICAL ADVICE OR AS A SCIENTIFIC PUBLICATION.

None of the products have been evaluated by The Food and Drug Administration, and are not for medical use. Their use in human or animal subjects is strictly prohibited by law, and they are available here only for in-vitro research purposes, by licensed professionals. By purchasing from this site, you agree to comply with our Terms and Conditions.